Solid Tumor, AdultPhase 2ICONICNCT07487805
Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)
A Phase 2 study testing Intermediate-dose ivermectin and High-dose ivermectin in people with Solid Tumor, Adult, run by University of Florida.
Trial summary
Public awareness of ivermectin's purported anticancer properties has led to widespread off-label use. In a 2023 cross-sectional study in Loja, Ecuador, 19% of respondents reported using ivermectin as an adjunct to cancer treatment. However, clinical data remain virtually absent. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Solid Tumor, Adult
- What is being tested?
- Intermediate-dose ivermectin and High-dose ivermectin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- Dec 2026to Dec 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically or clinically confirmed solid tumor malignancy for which the patient has been receiving an immune checkpoint inhibitor (ICI) as part of standard of care for ≥21 days prior to the first ivermectin dose, either alone or in combination with other systemic therapies. Both metastatic and (neo)adjuvant treatment settings are permitted.
- Adults ≥ 18 years of age.
- ECOG Performance Status of 0-2.
- Subjects must be able to swallow oral medication.
- Subjects must not have any known and active gastrointestinal disorders that impact absorption (e.g., inflammatory bowel disease, short bowel syndrome, severe diarrhea, prior major GI surgery [e.g., gastric bypass], or chronic vomiting) as determined by the investigator.
- Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.
- Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 4 weeks after the last dose of study drug to minimize the risk of pregnancy. Prior to study enrollment, subjects of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
- Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 4 weeks following the last dose of study drug.
Who cannot join
- Subjects who are currently taking, or have taken, ivermectin without a washout period prior to first treatment on study.
- Subjects can become eligible for study participation if they do a 2-week wash-out period prior to first treatment on study.
- Subjects who have received their first dose of ICI therapy <21 days before the baseline visit.
- Subjects can become eligible for study participation after ≥21 days have passed following Cycle 1 of ICI.
- Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after the last dose of study drug.
- Subjects who are confirmed to be pregnant or breastfeeding.
Show all 16Show fewer
- History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
- Administration of all vaccines within 30 days prior to the first dose of trial treatment and while on treatment.
- Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
- Rental function: Creatinine clearance ≤ 30 mL/min
- Hepatic function:
- Total bilirubin > 1.5 x ULN unless patients with Gilbert Syndrome (total bilirubin > 3 x ULN)
- Liver metastasis: AST/ALT > 5 x ULN
- Concomitant use of Strong CYP3A4 inhibitor for 7 days or 5 half-lives, whichever is longer
- Concomitant use of Strong CYP3A4 inducer for 14 days or 5 half-lives, whichever is longer
- QTc > 480 msec
About this study
Official title: Ivermectin Combined With Immune-Checkpoint Inhibition in Cancer (ICONIC)
Public awareness of ivermectin's purported anticancer properties has led to widespread off-label use. In a 2023 cross-sectional study in Loja, Ecuador, 19% of respondents reported using ivermectin as an adjunct to cancer treatment. However, clinical data remain virtually absent. To date, only one partially reported human study has investigated ivermectin in combination with anti-PD-1 therapy in patients with metastatic triple-negative breast cancer. Among the first nine treated patients, no treatment-related serious adverse events were observed, and the study remains ongoing.
Despite this growing interest, ivermectin's off-label use carries risks. For instance, Gilene et al. described a case of severe neurotoxicity in a patient with metastatic osteosarcoma receiving regorafenib, likely due to a pharmacokinetic interaction through CYP3A49. Moreover, the potential impact of ivermectin on the gut microbiome-a key modulator of immune checkpoint inhibitor (ICI) immunotherapy success or failure efficacy-remains poorly understood. As antibiotic exposure has been linked to diminished immunotherapy outcomes, ivermectin's antibiotic properties raise legitimate concerns about possible microbiome disruption. However, variables such as ivermectin dose, the duration of exposure, and the type of immunotherapy are each variables that remain poorly studied.
Read more
Taken together, these data underscore the urgency to prospectively evaluate ivermectin's immunologic effects in patients with cancer treated ICIs. Given ivermectin's wide availability, affordability, and public interest, rigorous clinical testing is crucial to determine whether it enhances-or potentially compromises-anticancer immunity while simultaneously assessing its safety to provide guidance for clinicians and patients.
This study will investigate the safety, pharmacodynamic effects, and potential for dose-responsive immune modulation of ivermectin given concurrently with immune checkpoint inhibitor therapy in adult subjects with solid tumors.
- Conditions
- Solid Tumor, Adult
- Being tested
- Intermediate-dose ivermectin, High-dose ivermectin
- Keywords
- immunotherapy, ivermectin, antitumor immune activation, microbiome, cancer
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intermediate-dose ivermectinDrug
Subjects on this arm will take 200 µg/kg of ivermectin orally from Day 1 through 3 weekly for 4 weeks while undergoing their standard immune checkpoint inhibitor treatment.
High-dose ivermectinDrug
Subjects on this arm will take 400 µg/kg of ivermectin orally from Day 1 through 3 weekly for 4 weeks while undergoing their standard immune checkpoint inhibitor treatment.
| Study group | Role | What they receive |
|---|---|---|
| Intermediate-dose ivermectin | Experimental | Not described Receives: Drug: Intermediate-dose ivermectin |
| High-dose ivermectin | Experimental | Not described Receives: Drug: High-dose ivermectin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Ki-67+HLA-DR+ non-naïve CD8 T-cells
Determine the median fold-change in Ki-67+HLA-DR+ non-naïve CD8 T-cells at week 2 of each experimental arm compared to baseline. The quantity of Ki-67+HLA-DR+ non-naïve CD8 T-cells will be measured by longitudinal flow cytometric immunophenotyping of peripheral blood mononuclear cells.
Measured: 2 weeks
Secondary outcomes (2)
Adverse events
Determine the number of NCI Common Terminology Criteria for Adverse Events (CTCAE) v6.0 grade ≥3 adverse events on each arm.
Measured: 118 days
Change in cytokines
Determine the fold-change in cytokines in peripheral blood from baseline to week 2, as measured by a Human Cytokine Luminex Performance Assay
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2026
- Study startDec 2026 (estimated)
- Primary completionSep 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid Tumor, AdultStudies of the same condition, open and under way.
- More trials run by University of FloridaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Florida
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Leighton Elliott, MD, Principal investigator, University of Florida
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07487805
- Sponsor's protocol ID
- UF-ETG-004
- Other IDs
- IRB202501760
- Acronym
- ICONIC
- Status last verified
- Oct 2026
- First submitted
- 17 Mar 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ivermectin Combined With Immune-Checkpoint Inhibition in Cancer (ICONIC)
- ClinicalTrials.gov ID
- NCT07487805
- Acronym / sponsor ID
- ICONIC / UF-ETG-004
- Conditions
- Solid Tumor, Adult
- Keywords
- immunotherapy, ivermectin, antitumor immune activation, microbiome, cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University of FloridaUniversity, hospital or other
- Study start
- Dec 2026 (estimated)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 23 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Public awareness of ivermectin's purported anticancer properties has led to widespread off-label use. In a 2023 cross-sectional study in Loja, Ecuador, 19% of respondents reported using ivermectin as an adjunct to cancer treatment. However, clinical data remain virtually absent. To date, only one partially reported human study has investigated ivermectin in combination with anti-PD-1 therapy in patients with metastatic triple-negative breast cancer. Among the first nine treated patients, no treatment-related serious adverse events were observed, and the study remains ongoing.
Despite this growing interest, ivermectin's off-label use carries risks. For instance, Gilene et al. described a case of severe neurotoxicity in a patient with metastatic osteosarcoma receiving regorafenib, likely due to a pharmacokinetic interaction through CYP3A49. Moreover, the potential impact of ivermectin on the gut microbiome-a key modulator of immune checkpoint inhibitor (ICI) immunotherapy success or failure efficacy-remains poorly understood. As antibiotic exposure has been linked to diminished immunotherapy outcomes, ivermectin's antibiotic properties raise legitimate concerns about possible microbiome disruption. However, variables such as ivermectin dose, the duration of exposure, and the type of immunotherapy are each variables that remain poorly studied.
Taken together, these data underscore the urgency to prospectively evaluate ivermectin's immunologic effects in patients with cancer treated ICIs. Given ivermectin's wide availability, affordability, and public interest, rigorous clinical testing is crucial to determine whether it enhances-or potentially compromises-anticancer immunity while simultaneously assessing its safety to provide guidance for clinicians and patients.
This study will investigate the safety, pharmacodynamic effects, and potential for dose-responsive immune modulation of ivermectin given concurrently with immune checkpoint inhibitor therapy in adult subjects with solid tumors.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intermediate-dose ivermectin | Experimental | Drug: Intermediate-dose ivermectin |
| High-dose ivermectin | Experimental | Drug: High-dose ivermectin |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Histologically or clinically confirmed solid tumor malignancy for which the patient has been receiving an immune checkpoint inhibitor (ICI) as part of standard of care for ≥21 days prior to the first ivermectin dose, either alone or in combination with other systemic therapies. Both metastatic and (neo)adjuvant treatment settings are permitted.
- Adults ≥ 18 years of age.
- ECOG Performance Status of 0-2.
- Subjects must be able to swallow oral medication.
- Subjects must not have any known and active gastrointestinal disorders that impact absorption (e.g., inflammatory bowel disease, short bowel syndrome, severe diarrhea, prior major GI surgery [e.g., gastric bypass], or chronic vomiting) as determined by the investigator.
Key exclusion criteria (16 listed)
- Subjects who are currently taking, or have taken, ivermectin without a washout period prior to first treatment on study.
- Subjects who have received their first dose of ICI therapy <21 days before the baseline visit.
- Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after the last dose of study drug.
- Subjects who are confirmed to be pregnant or breastfeeding.
- History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intermediate-dose ivermectinSubjects on this arm will take 200 µg/kg of ivermectin orally from Day 1 through 3 weekly for 4 weeks while undergoing their standard immune checkpoint inhibitor treatment. | Drug | Intermediate-dose ivermectin |
| High-dose ivermectinSubjects on this arm will take 400 µg/kg of ivermectin orally from Day 1 through 3 weekly for 4 weeks while undergoing their standard immune checkpoint inhibitor treatment. | Drug | High-dose ivermectin |
Primary outcome
Change in Ki-67+HLA-DR+ non-naïve CD8 T-cells
Time frame: 2 weeks
Determine the median fold-change in Ki-67+HLA-DR+ non-naïve CD8 T-cells at week 2 of each experimental arm compared to baseline. The quantity of Ki-67+HLA-DR+ non-naïve CD8 T-cells will be measured by longitudinal flow cytometric immunophenotyping of peripheral blood mononuclear cells.
2 secondary outcomes
Adverse events
Time frame: 118 days
Change in cytokines
Time frame: 2 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
Related trials for Solid Tumor, Adult
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
Active, not recruitingPhase 1
Advanced or Recurrent Solid Tumors Treated With SHetA2
Solid Tumor, Adult
RecruitingObservational study
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Very Rare Tumors, Very Rare Cancers
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
RecruitingPhase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Solid Tumor, Advanced Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Leighton Elliott, MD principal investigator
University of Florida
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Intermediate-dose ivermectin and High-dose ivermectin in people with Solid Tumor, Adult, run by University of Florida.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Ki-67+HLA-DR+ non-naïve CD8 T-cells (time frame: 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.